The S&P 500's (^GSPC) top ten companies have faced a significant downturn this year, with a combined market cap loss of $2.5 ...

Dr. Richard Law, a former Exscientia executive who helped build the company and facilitate its merger with Recursion ...

President Donald J. Trump has turbocharged his pledge to transform America into a global manufacturing titan, securing a ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier. Ricks' payout included $19.7 million in ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

Investing.com-- Eli Lilly and Company (NYSE:LLY) said on Tuesday evening that China’s food and drug regulator had approved its ...

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate ...

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly. Also, EPS is estimated to ramp higher this year by +27.4%.